Abstract:APOB is major lipid binding proteins of low-density lipoprotein (LDL) particles and responsible for carrying fat molecules to cells within all tissues. High levels of APOB are known to be related to heart disease and vascular disease. Interestingly, recent The Cancer Genome Atlas (TCGA) study revealed that APOB is one of frequently mutated genes in multiple cancers including melanoma, liver cancer, stomach, esophageal, head and neck, uterine, and lung cancers (from >20 to 10%). Majority mutations are considered to cause loss of function as they are truncation mutations, suggesting that APOB might have tumor suppressive activity. However, because of its physiological roles in circulating fat molecules in our body, APOB has never been studied in cancer-related setting and thus its clinical relevance or biological roles of APOB in cancer development is currently unknown. Here we show that loss of APOB in hepatocellular carcinoma (HCC) is significantly associated with poor survival of HCC patients by applying comparative genomics approach that integrate genomic data from mouse and human HCC tumors. We further show that loss of APOB leads to shifting balance of lipid metabolisms favoring for tumor growth. For development of genomic signature reflecting hepatic APOB activity and test and validation of its association with prognosis, we used unsupervised approach combined with supervised prediction models by integrating gene expression data from mouse models and human HCC. When HCC patients were stratified into APOB-active and APOB-inactive subgroups, overall survival (OS) rate and recurrence free survival (RFS) rate of patients in APOB-inactive group is significantly lower than those in APOB-active (P Apob -silenced livers are direct downstream targets of Erbb2 , Vegfa , and regulator of metastasis and cancer initiation cells Cd44 . Consistent with activation of many tumor-promoting regulators, Tp53 , a major tumor suppressor, was inactivated in Apob -silenced livers, suggesting that loss of Apob in the liver may provoke initiation of tumor development. More interestingly, proliferation of three liver cancer cells was significantly increased when expression of APOB was silenced by siRNAs, further suggesting functional roles of APOB in tumor development. For the first time, we showed that APOB inactivation has a clinical impact in HCC patients with significant alteration in regulators associated with tumorigenesis. Citation Format: Gena Lee, Yun Seong Jeong, Min Jun Kwak, Kim DoWon, Ju-Seog Lee, Yim Sun Young. Loss of function mutations in APOB and their clinical significance in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3474.

Low APOA-1 Expression in Hepatocellular Carcinoma Patients Is Associated With DNA Methylation and Poor Overall Survival

Low Expression of APOB Mrna or Its Hypermethylation Predicts Favorable Overall Survival in Patients with Low-Grade Glioma.

Impact of apolipoprotein A1 on tumor immune microenvironment, clinical prognosis and genomic landscape in hepatocellular carcinoma

Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma

The Association Between Methylation Patterns of DNAH17 and Clinicopathological Factors in Hepatocellular Carcinoma

Decreased Expression of ApoF Associates with Poor Prognosis in Human Hepatocellular Carcinoma

Apolipoprotein B is Associated with the Microenvironment of Cholangiocarcinoma

Apobec3g Expression is Correlated with Poor Prognosis in Colon Carcinoma Patients with Hepatic Metastasis

APOB is a potential prognostic biomarker in hepatocellular carcinoma

Apolipoprotein A1: a Novel Serum Biomarker for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection

Clinical significance of apolipoprotein F in prognosis of patients with hepatocellular carcinoma

Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma

Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma

Apolipoprotein H-based Prognostic Risk Correlates with Liver Lipid Metabolism Disorder in Patients with HBV-related Hepatocellular Carcinoma.

Abstract 3474: Loss of function mutations in APOB and their clinical significance in hepatocellular carcinoma

Apolipoprotein C1 (APOC1) Promotes Tumor Progression Via MAPK Signaling Pathways in Colorectal Cancer.

Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma

A prognostic model based on DNA methylation-related gene expression for predicting overall survival in hepatocellular carcinoma

Prognostic Value of Serum Apolipoprotein B to Apolipoprotein A-I Ratio in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis

Promoter aberrant methylation status of ADRA1A is associated with hepatocellular carcinoma